Trump administration finalizes rule to end federal support for gender-affirming care

The Trump administration has finalized a rule to end federal support for gender-affirming care through Medicaid and the Children’s Health Insurance Program (Chip), a move that will make it harder for vulnerable children to access healthcare. The rule, set to take effect on 13 October, was first proposed in December and received nearly 35,000 comments, with about 90% of them opposing the change. Ma’ayan Anafi, senior counsel for health equity and justice at the National Women’s Law Center (NWLC), described the rule as "incredibly dangerous" and stated that it is "not about following the science" but rather about promoting the administration's anti-transgender agenda. The key figure in this story is the US Department of Health and Human Services (HHS), which pointed to international reviews of medical evidence, such as the Cass Review in the United Kingdom, to justify the rule, while ignoring more recent landmark reports that find gender-affirming care to be safe and effective.

The most significant consequence of this rule is that it will make it harder for vulnerable children to access healthcare, particularly those who are enrolled in Medicaid and Chip. These programs are crucial for providing healthcare to low-income families, and the restriction on gender-affirming care will have a disproportionate impact on these communities. The HHS has argued that the rule is necessary because there is not enough evidence to support the safety and effectiveness of gender-affirming care, but experts and advocates disagree, citing numerous studies that demonstrate the benefits of such care. The NWLC has outlined concerns about the rule, including the lack of evidence to support it and the potential harm it could cause to transgender youth. The rule is also seen as part of a broader effort by the Trump administration to restrict access to healthcare for transgender individuals, including a proposed rule that would prevent health systems from providing gender-affirming care to anyone, regardless of age. The administration's actions have been widely criticized, with a federal judge blocking one such effort in April, citing the HHS secretary's "wanton disregard" for the law and the harm it could cause to real people.

The implications of this rule are far-reaching, and it is likely to have a significant impact on the lives of transgender youth and their families. If the rule takes effect, children on Medicaid and Chip will be given up to six months to taper off their medications, which could lead to serious health consequences. States could potentially use their portion of Medicaid funds to cover gender-affirming care, but this would require significant resources and effort. Individuals and organizations may also need to ramp up mutual aid efforts to support those affected by the rule. The Trump administration's focus on the cost of gender-affirming care has been criticized as a pretext for restricting access to care, and advocates argue that the rule is based on prejudice rather than evidence. As Anafi noted, "Whenever we see restrictions on care that are based on politics and ideology, we know that patients are ultimately suffering." The rule is likely to face legal challenges, which could delay or block its implementation, but in the meantime, it will continue to cause distress and harm to the transgender community.

⚡ Effects Interpreter